PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Rotigotine - Restless Leg Syndrome
PAD Profile : Rotigotine - Restless Leg Syndrome
Keywords :
dopamine receptor agonists
Brand Names Include :
Neupro
Traffic Light Status
Status 1 of 1.
Status :
Green
Important
Preferred
Formulations :
- Patches
Important Information :
Patients with severe symptoms, who are obese, co-morbid depression, increased risk of falls or cognitive impairment. Consider use of patch if significant daytime symptoms as it has a long duration of action.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
No guidelines returned.
Other Drugs
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
07 November 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Rotigotine is recommended as a FIRST line option for the treatment of Restless Leg Syndrome, as per CKS guidance.
Link to CKS page - https://cks.nice.org.uk/restless-legs-syndrome
Associated BNF Codes
04. Central Nervous System
04.09.01. Dopaminergic drugs used in parkinsonism